重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用

Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma

背景与目的肺鳞癌是非小细胞肺癌常见的病理类型,晚期肺鳞癌是一种无法治愈的恶性肿瘤。抗血管生成药物与传统化疗联合能够为患者带来生存改善。本研究分析了重组人血管内皮抑制素(恩度)联合化疗治疗晚期肺鳞癌的疗效及安全性。方法回顾性分析中国医学科学院肿瘤医院内科2011年11月-2015年5月采用人血管内皮抑制素联合传统化疗方案治疗的15例晚期肺鳞癌患者的近期疗效、毒副反应及无进展生存时间。结果 14例可评估患者中疗效评价最佳即为部分缓解5例(35.7%)、疾病稳定7例(50.0%)、疾病进展2例(14.3%),客观缓解率为35.7%,疾病控制率为85.7%,中位无进展生存为9.3个月。全组患者治疗耐受良好,3度不良反应表现为中性粒细胞减少(2/15,13.3%)和呕吐(1/15,6.7%),其余不良事件均为1度/2度。结论重组人血管内皮抑制素联合化疗治疗晚期肺鳞癌可取得较好的客观疗效并且安全性良好。

Background and objective Squamous cell carcinoma（SCC） is a common pathological type of nonsmall cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients＇ survival time. The aim of the study was to analyze the efficacy and safety of recombinant human endostatin（Endostar） in treating advanced lung SCC. Methods We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed. Results Among the evaluble 14 patients, the best overall response was partial response in 5 patients（35.7%）, stable disease in 7 patients（50.0%）, and progressive disease in 2 patients（14.3%）. The objective response rate（ORR） was 35.7%, and disease control rate（DCR） was 85.7%. The median progression-free survival（PFS） was 9.3 months. The main grade 3 toxicity was neutropenia（2/15, 13.3%） and vomitting（1/15, 6.7%）. Conclusion Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.